nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.12.2015 | Original Article

Seasonal variations in vitamin D in relation to growth in short prepubertal children before and during first year growth hormone treatment

verfasst von: B. Andersson, D. Swolin-Eide, B. Kriström, L. Gelander, P. Magnusson, K. Albertsson-Wikland

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study investigated the relationship between seasonal variations in 25-hydroxyvitamin D (25(OH)D) levels and growth in prepubertal children during both the pretreatment year and the first year of GH treatment.

Methods

The study included 249 short prepubertal children with a broad range of GH secretion, GH_max during a 24 h profile median 23; range 1–127 mU/L, 191 boys (mean age ± SD, 8.6 ± 2.6 years), 58 girls (7.5 ± 1.9 years) receiving GH treatment (mean 43 µg/kg/day; range 17–99 µg/kg/day). Serum 25(OH)D was measured using an automated IDS-iSYS immunoassay.

Results

25(OH)D levels showed seasonal variation, and decreased significantly during GH treatment. 25(OH)D levels at start and first year reduction in 25(OH)D, correlated (−) with the first year growth response during treatment. The degree of GH secretion capacity within our study population of mainly non-GH deficient children and 25(OH)D sufficient (67 ± 29 nmol/L) had no influence on 25(OH)D levels. Growth during GH treatment were independent of seasonal variations in 25(OH)D. Multiple regression analysis showed that 25(OH)D levels at treatment start, together with auxological data and IGF-binding protein-3_SDS, explained 61 % of the variation in first year gain in height_SDS.

Conclusion

25(OH)D levels were associated with first year growth response to GH and may be a useful contribution to future growth prediction models.

Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–281. doi:10.1056/NEJMra070553 CrossRefPubMed

Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96(1):53–58. doi:10.1210/jc.2010-2704 PubMedCentralCrossRefPubMed

Holick MF (2008) Vitamin D: a D-Lightful health perspective. Nutr Rev 66(10 Suppl 2):S182–S194. doi:10.1111/j.1753-4887.2008.00104.x CrossRefPubMed

Stamp TC, Round JM (1974) Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature 247(5442):563–565CrossRefPubMed

Kuhn T, Kaaks R, Teucher B, Hirche F, Dierkes J, Weikert C, Katzke V, Boeing H, Stangl GI, Buijsse B (2014) Dietary, lifestyle, and genetic determinants of vitamin D status: a cross-sectional analysis from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany study. Eur J Nutr 53(3):731–741. doi:10.1007/s00394-013-0577-8 CrossRefPubMed

Toss G, Magnusson P (2012) Vitamin D status: sunshine is nice but other factors prevail. Eur J Nutr 51(2):255–256CrossRef

Klaus G, Merke J, Eing H, Hugel U, Milde P, Reichel H, Ritz E, Mehls O (1991) 1,25(OH)2D3 receptor regulation and 1,25(OH)2D3 effects in primary cultures of growth cartilage cells of the rat. Calcif Tissue Int 49(5):340–348CrossRefPubMed

Schwartz Z, Schlader DL, Ramirez V, Kennedy MB, Boyan BD (1989) Effects of vitamin D metabolites on collagen production and cell proliferation of growth zone and resting zone cartilage cells in vitro. J Bone Miner Res 4(2):199–207. doi:10.1002/jbmr.5650040211 CrossRefPubMed

Schwartz Z, Brooks B, Swain L, Del Toro F, Norman A, Boyan B (1992) Production of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 by growth zone and resting zone chondrocytes is dependent on cell maturation and is regulated by hormones and growth factors. Endocrinology 130(5):2495–2504PubMed

10.

Gerstenfeld LC, Kelly CM, Von Deck M, Lian JB (1990) Effect of 1,25-dihydroxyvitamin D3 on induction of chondrocyte maturation in culture: extracellular matrix gene expression and morphology. Endocrinology 126(3):1599–1609CrossRefPubMed

11.

Yamamoto Y, Yoshizawa T, Fukuda T, Shirode-Fukuda Y, Yu T, Sekine K, Sato T, Kawano H, Aihara K, Nakamichi Y, Watanabe T, Shindo M, Inoue K, Inoue E, Tsuji N, Hoshino M, Karsenty G, Metzger D, Chambon P, Kato S, Imai Y (2013) Vitamin d receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology 154(3):1008–1020. doi:10.1210/en.2012-1542 CrossRefPubMed

12.

Nilsson O, Marino R, De Luca F, Phillip M, Baron J (2005) Endocrine regulation of the growth plate. Horm Res 64(4):157–165CrossRefPubMed

13.

Albertsson-Wikland K, Alm F, Aronsson S, Gustafsson J, Hagenas L, Hager A, Ivarsson S, Kristrom B, Marcus C, Moell C, Nilsson KO, Ritzen M, Tuvemo T, Westgren U, Westphal O, Aman J (1999) Effect of growth hormone (GH) during puberty in GH-deficient children: preliminary results from an ongoing randomized trial with different dose regimens. Acta Paediatr Suppl 88(428):80–84CrossRefPubMed

14.

Albertsson-Wikland K, Kristrom B, Lundberg E, Aronson AS, Gustafsson J, Hagenas L, Ivarsson SA, Jonsson B, Ritzen M, Tuvemo T, Westgren U, Westphal O, Aman J (2014) Growth hormone dose-dependent pubertal growth: a randomized trial in short children with low growth hormone secretion. Horm Res Paediatr 82(3):158–170. doi:10.1159/000363106 CrossRefPubMed

15.

Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenas L, Ivarsson SA, Jonsson B, Kristrom B, Marcus C, Nilsson KO, Ritzen EM, Tuvemo T, Westphal O, Aman J (2008) Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab 93(11):4342–4350CrossRefPubMed

16.

Gelander L, Karlberg J, Albertsson-Wikland K (1994) Seasonality in lower leg length velocity in prepubertal children. Acta Paediatr 83(12):1249–1254CrossRefPubMed

17.

Land C, Blum WF, Stabrey A, Schoenau E (2005) Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency. Eur J Endocrinol 152(5):727–733. doi:10.1530/eje.1.01899 CrossRefPubMed

18.

Shulman DI, Frane J, Lippe B (2013) Is there “seasonal” variation in height velocity in children treated with growth hormone? Data from the national cooperative growth study. Int J Pediatr Endocrinol 1:2. doi:10.1186/1687-9856-2013-2 CrossRef

19.

Kristrom B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K (2009) Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab 94(2):483–490CrossRefPubMed

20.

Albertsson-Wikland K, Kristrom B, Rosberg S, Svensson B, Nierop AF (2000) Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res 48(4):475–484CrossRef

21.

Bodnar LM, Catov JM, Wisner KL, Klebanoff MA (2009) Racial and seasonal differences in 25-hydroxyvitamin D detected in maternal sera frozen for over 40 years. Br J Nutr 101(2):278–284. doi:10.1017/S0007114508981460 PubMedCentralCrossRefPubMed

22.

Karlberg J (1989) On the construction of the infancy-childhood-puberty growth standard. Acta Paediatr Scand Suppl 356:26–37CrossRefPubMed

23.

Albertsson-Wikland K, Luo ZC, Niklasson A, Karlberg J (2002) Swedish population-based longitudinal reference values from birth to 18 years of age for height, weight and head circumference. Acta Paediatr 91(7):739–754CrossRef

24.

Niklasson A, Albertsson-Wikland K (2008) Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr 8:8. doi:10.1186/1471-2431-8-8 PubMedCentralCrossRefPubMed

25.

Karlberg J, Luo ZC, Albertsson-Wikland K (2001) Body mass index reference values (mean and SD) for Swedish children. Acta Paediatr 90(12):1427–1434CrossRefPubMed

26.

Luo ZC, Albertsson-Wikland K, Karlberg J (1998) Target height as predicted by parental heights in a population-based study. Pediatr Res 44(4):563–571CrossRefPubMed

27.

Penny R, Blizzard RM, Davis WT (1969) Sequential arginine and insulin tolerance tests on the same day. J Clin Endocrinol Metab 29(11):1499–1501. doi:10.1210/jcem-29-11-1499 CrossRefPubMed

28.

Albertsson-Wikland K, Rosberg S (1988) Analyses of 24 hour growth hormone profiles in children: relation to growth. J Clin Endocrinol Metab 67(3):493–500CrossRefPubMed

29.

Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson-Wikland K (1997) Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin Chem 43(6 Pt 1):950–956PubMed

30.

Le Goff C, Peeters S, Crine Y, Lukas P, Souberbielle JC, Cavalier E (2012) Evaluation of the cross-reactivity of 25-hydroxyvitamin D2 on seven commercial immunoassays on native samples. Clin Chem Lab Med 50(11):2031–2032. doi:10.1515/cclm-2012-0164 PubMed

31.

Löfqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson-Wikland K (2001) Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab 86(12):5870–5876CrossRefPubMed

32.

Lofqvist C, Andersson E, Gelander L, Rosberg S, Hulthen L, Blum WF, Wikland KA (2005) Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. J Clin Endocrinol Metab 90(3):1420–1427CrossRefPubMed

33.

Wei S, Tanaka H, Kubo T, Ono T, Kanzaki S, Seino Y (1997) Growth hormone increases serum 1,25-dihydroxyvitamin D levels and decreases 24,25-dihydroxyvitamin D levels in children with growth hormone deficiency. Eur J Endocrinol 136(1):45–51CrossRefPubMed

34.

Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G (1993) Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 122(1):37–45CrossRefPubMed

35.

Ciresi A, Ciccio F, Giordano C (2014) High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement treatment. J Endocrinol Invest 37(7):631–638. doi:10.1007/s40618-014-0084-7 CrossRefPubMed

36.

Hypponen E, Fararouei M, Sovio U, Hartikainen AL, Pouta A, Robertson C, Whittaker JC, Jarvelin MR (2011) High-dose vitamin D supplements are not associated with linear growth in a large Finnish cohort. J Nutr 141(5):843–848. doi:10.3945/jn.110.133009 CrossRefPubMed

37.

Hochberg Z (2003) Vitamin D and Rickets. S Karger AG, BaselCrossRef

38.

Bellone S, Esposito S, Giglione E, Genoni G, Fiorito C, Petri A, Bona G, Prodam F (2014) Vitamin D levels in a paediatric population of normal weight and obese subjects. J Endocrinol Invest 37(9):805–809. doi:10.1007/s40618-014-0108-3 CrossRefPubMed

39.

Holick MF, Schnoes HK, DeLuca HF, Gray RW, Boyle IT, Suda T (1972) Isolation and identification of 24,25-dihydroxycholecalciferol, a metabolite of vitamin D made in the kidney. Biochemistry 11(23):4251–4255CrossRefPubMed

40.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930. doi:10.1210/jc.2011-0385 CrossRefPubMed

41.

Bailey D, Colantonio D, Kyriakopoulou L, Cohen AH, Chan MK, Armbruster D, Adeli K (2013) Marked biological variance in endocrine and biochemical markers in childhood: establishment of pediatric reference intervals using healthy community children from the CALIPER cohort. Clin Chem 59(9):1393–1405. doi:10.1373/clinchem.2013.204222 CrossRefPubMed

42.

Franchi B, Piazza M, Sandri M, Tenero L, Comberiati P, Boner AL, Capristo C (2014) 25-hydroxyvitamin D serum level in children of different ethnicity living in Italy. Eur J Pediatr. doi:10.1007/s00431-014-2451-y

43.

Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R (2013) Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369(21):1991–2000. doi:10.1056/NEJMoa1306357 PubMedCentralCrossRefPubMed

Titel: Seasonal variations in vitamin D in relation to growth in short prepubertal children before and during first year growth hormone treatment
verfasst von: B. Andersson
D. Swolin-Eide
B. Kriström
L. Gelander
P. Magnusson
K. Albertsson-Wikland
Publikationsdatum: 01.12.2015
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 12/2015
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0360-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma

Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings

The impact of vitamin D levels on glycemic control and bone mineral density in postmenopausal women with type 2 diabetes

Should we change our mind about second trimester biochemical aneuploidy screening markers of patients with polycystic ovary syndrome?

Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case–control study